European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Omicron lineages, and especially BA.5, were determined to have higher reinfection rates and lower disease severity than previously circulating variants of concern.

Patients who contracted COVID-19 later in the pandemic (2021-2022) were more likely to develop new chronic diseases after infection than patients who caught COVID-19 in 2020.

Anemia is both common and independently associated with poor clinical outcomes in respiratory infections, including COVID-19.

The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) voted 12-0 in favor of recommending this antibiotic and sets up a PDUFA target action date of May 29.

Since the lifting of public health restrictions, the country saw a sizable increase in incidence rates.

Post-COVID-19 conditions were more common in unvaccinated children than in children who had received at least 1 dose of a COVID-19 vaccine.

With an FDA approval, it would be the first new class of oral antibiotics for uncomplicated urinary tract infections (uUTI) in over 20 years.

Poor sleep quality, deterioration in sleep quality, and sleep regularity were all linked to impaired lung function.

Several years after its FDA approval, this antibiotic continues to prove its efficacy in vitro across various pathogens related to these infections.

Alita Miller, PhD, senior vice president of research at Entasis Therapeutics, discusses positive trial data for Sulbactam-durlobactam (SUL-DUR) slated to be presented at ECCMID 2023.

A new study presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) examined a rapid cellular host response test designed to aid providers who are working in emergency departments and need quick, efficient diagnostic information.

The case and another probable case is being presented at next week’s European Congress of Clinical Microbiology & Infectious Diseases conference.

Lasting 505 days, investigators documented the longest known COVID-19 infection. The research, presented at ECCMID, also found one of the first cases of occult COVID-19, in which a patient who tests negative is later found to have ongoing COVID-19.

An ECCMID study found COVID-19 primary infections were more severe than reinfections, and vaccination further reduced symptoms.

Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.

During the pandemic, antibiotic-resistant bacterial infections increased in hospitalized patients who tested positive or negative for COVID-19.

One study, presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), found waiting longer in between the first and second Pfizer-BioNTech vaccine doses boosted immune response 9-fold.

Today at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Shionogi presented late-breaking data from their phase 2/3 clinical trial for S-217622, an investigational 3CL protease inhibitor. On day 4 of treatment with Shionogi’s S-217622, COVID-19 positive viral titers decreased by 90%.

The MOVe-OUT study will continue to the phase 3 portion and evaluate 800 mg of the therapy administered twice daily.

Those taking methotrexate had lower seroconversion rates compared to controls.

While infection risk is not eliminated, the vaccine still provided significant protection.

The second wave in South Africa was larger and saw the Beta lineage dominate.

Investigators followed patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) for 6 months to review their outcomes.

A Swiss population-based study showed more people in socioeconomically challenged places tested positive more frequently, saw higher hospitalizations, and greater mortality rates than those in higher socioeconomic places.

Azithromycin versus standard care in patients with mild-to-moderate COVID-19, did not reduce the risk of hospital admission or mortality.

A dosage of 250 mg twice daily for 10 days was confirmed for the next phase of trials after achieving initial and sustained cure in 100% of patients.

Oral ibrexafungerp could cut hospital stays for patients with invasive candidiasis infections.

It is known that the type of respiratory specimen, sampling environmental factors, and time from symptom onset impact the sensitivity of rapid influenza diagnostic tests.

Investigators say they consider cefiderocol a candidate for therapeutic drug monitoring.

The data were released as part of the now-cancelled European Congress of Clinical Microbiology and Infectious Diseases.